Blue Clay Capital Management’s Galectin Therapeutics GALT Stock Holding History

Blue Clay Capital Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-74,205	Closed	-$122K	–	124
2015 Q4	$122K	Sell	74,205 -262	-0.4%	-$600	0.1%	107
2015 Q3	$174K	Hold	74,467	–	–	0.14%	88
2015 Q2	$203K	Buy	+74,467	New	+$225K	0.11%	78

Other funds holding GALT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Blue Clay Capital Management's GALT Position: Q1 2016 in Review

Blue Clay Capital Management sold out of Galectin Therapeutics (GALT) in Q1 2016, closing a stake of 74,205 shares — an estimated $122K sold.

Blue Clay Capital Management first reported a position in GALT in Q2 2015 and held it in 3 quarters. The position peaked at $203K in Q2 2015. 50 funds tracked by Wall St. Rank hold GALT as of Q1 2016.

Blue Clay Capital Management reported no remaining Galectin Therapeutics position as of Q1 2016 after selling out during the quarter.
Blue Clay Capital Management sold 74,205 Galectin Therapeutics shares in Q1 2016, an estimated $122K.
Blue Clay Capital Management first reported a position in Galectin Therapeutics in Q2 2015 and held it in 3 quarters.
Blue Clay Capital Management's Galectin Therapeutics position peaked at $203K in Q2 2015.
50 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2016.

Based on Blue Clay Capital Management's 13F filing for Q1 2016, filed 16 May 2016.